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Dietary intake of 18: 2n-6 and 18: 3n-3 may affect endogenous production and incorporation of n-3 long-chain PUFA (LCPUFA) from fish oils
(FO). This double-blinded controlled 2 £ 2-factorial 8-week intervention investigates the effects of high and low 18: 2n-6 intake in combination
with FO-supplementation on tissue fatty acid composition. Healthy young men (n 64) were randomized to capsules with FO or olive oil (control)
(4·4 (2·0–5·6) ml/d) and to either sunflower oil and margarine (S/B) or rapeseed oil and a butter spread (R/K) to provide a high or a low 18: 2n-6
intake. Diet was measured by 4-d weighed dietary records at baseline, during and 8 weeks after the intervention and tissue incorporation as
fatty acid composition of peripheral blood mononuclear cells (PBMC). The fat intervention gave a mean difference in the 18: 2n-6 intake of
7·3 g/d (95 % CI 4·6, 10·0) and a similar 18: 3n-3 intake in the groups. The R/K groups had a 0·2 % fatty acid (FA%) (95 % CI 0·0, 0·4,
P¼0·02) higher content of 22: 5n-3 in the PBMC, a tendency of slightly higher 20: 5n-3 (P¼0·06), but no more 22: 6n-3 (P¼0·83) than
the S/B groups. FO effectively raised the PBMC content of all n-3 LCPUFA (P,0·001). The fat intervention did not markedly influence the
effect of FO; the mean PBMC content of n-3 LCPUFA was 10·3 (SEM 0·3) FA% in the FO þ S/B group and 10·6 (SEM 0·2) FA% in
the FO þ R/K group. In conclusion, increasing the 18: 2n-6 intake did not have any pronounced effect on incorporation of n-3 LCPUFA
in PBMC, either alone or with simultaneous FO supplementation.
PUFA: Fish oil: Incorporation: Mononuclear cell: Linoleic acid
Since the 1960s, people in the Western world have been
encouraged to increase their consumption of PUFA in order
to decrease serum cholesterol concentrations1. Today, PUFA
account for up to 12 % total energy intake (E%)2,3 and n-6
PUFA, in particular linoleic acid (18: 2n-6), constitute up to
90–95 % of these dietary PUFA4. An increased intake of
18: 2n-6 has been shown to lower CVD end-points5, but
Israelis, who traditionally have high intakes of 18: 2n-6,
have been shown to have a high CVD mortality rate3.
Furthermore, the possible harmful effects of n-6 PUFA on
inflammatory diseases and cancer risk have been disputed6,7.
High dietary and tissue levels of n-3 PUFA, especially n-3
long-chain PUFA (LCPUFA), have been associated with a
protective effect on CVD and other chronic illnesses2,8,9.
The n-3 and n-6 PUFA compete metabolically with regard
to tissue incorporation and conversion to active paracrine
substances (e.g. eicosanoids)10. Therefore, it has been argued
that the amount of 18: 2n-6 in the diet should be taken into
account when designing studies and dietary recommendations
on n-3 PUFA2.
Fish and fish oils (FO) are major dietary sources of n-3
LCPUFA, primarily DHA (22: 6n-3) and EPA (20: 5n-3).
n-3 LCPUFA can be produced endogenously from a-linolenic
acid (18: 3n-3), but the conversion is limited because of
b-oxidation and competition for the rate-limiting enzyme,
D6-desaturase10. This enzyme is involved in conversion of
18: 3n-3 to 20: 5n-3 and likely also in a second round of
conversion to 22: 6n-311. It is also involved in metabolism
of 18: 2n-6 to arachidonic acid (20: 4n-6)10. Accordingly,
production of 22: 6n-3 from 18: 3n-3 is thought to depend
on the amount of available substrate (18: 3n-3) and the
amount of 18: 2n-6, but may also be limited by the total
amount of 18: 2n-6 þ 18: 3n-3 in the diet12.
Many human trials studying the impact of dietary 18: 3n-3
and 18: 2n-6 on tissue n-3 LCPUFA and health have failed to
show more than marginal increases in synthesis and incorpor-
ation of 22: 6n-3, as a result of decreasing the 18: 2n-6:18:
3n-3 ratio (see 11). However, most have focused on increas-
ing the intake of 18: 3n-313 – 18, without considering the fact
that as a substrate for the D6-desaturase, 18: 3n-3 may inhibit
the conversion of docosapentaenoic acid (22: 5n-3) to 22:
6n-3. In an experiment where 18: 3n-3 was varied at a
constant intake of 18: 2n-6, Blank et al.12 found maximal
incorporation of 22: 6n-3 in piglets when the dietary
*Corresponding author: Dr Camilla T. Damsgaard, fax þ45 3533 2483, email ctd@life.ku.dk
Abbreviations: E%, percentage of total energy intake; FO, fish oil; LCPUFA, long-chain PUFA; OO, olive oil; PBMC, peripheral blood mononuclear cells.
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18: 2n-6:18: 3n-3 ratio was 2:1 to 4:1, whereas both higher and
lower ratios (the latter equivalent to both higher 18: 3n-3 and
higher total C18 PUFA intake) gave lower incorporation.
Therefore, both the dietary 18: 2n-6:18: 3n-3 ratio and the
total consumption of C18 PUFA are likely to affect the
endogenous 22: 6n-3 production12. To our knowledge, only
one randomized trial19 has investigated n-3 LCPUFA incor-
poration in human subjects at dietary n-6:n-3 PUFA ratios
below 7:1 in combination with a 18: 2n-6 intake of less
than 4 E%, without strongly increasing dietary 18: 3n-3.
Moreover, none of the studies13 – 15,17 – 19 investigated how
tissue levels of n-3 LCPUFA are affected by a change in
18: 2n-6 intake in combination with FO-supplementation.
This is interesting since it has been argued that a high
intake of 18: 2n-6 impairs the health benefits of FO by
decreasing the tissue incorporation of dietary n-3 LCPUFA2.
We supplemented sixty-four healthy men with FO or
control (olive oil, OO) capsules in combination with differ-
ent spreads and oils to provide a high or a low dietary 18:
2n-6 intake for 8 weeks. Diet and fatty acid composition of
peripheral blood mononuclear cells (PBMC) were measured
immediately before and after the intervention and after 8
weeks of wash-out, to assess whether any changes persisted
after the participants had returned to their normal diet.
PBMC was chosen as our model tissue since another pur-
pose of the study was to investigate inflammatory effects,
which is not reported in the present paper. We hypothesized
that providing commercially available oils and spreads,
which were high in 18: 2n-6, would increase the partici-
pants’ 18: 2n-6 intake and the dietary ratio of n-6:n-3
PUFA and that this would result in a lower incorporation
of 22: 6n-3 in PBMC. We also hypothesized that a high
consumption of 18: 2n-6 would impair the incorporation
of n-3 LCPUFA from FO-supplements. We tested this in a
realistic setting in which the fats used by the participants
on bread and for cooking were replaced with other
commonly used types.
Methods
Study design and recruitment
The present study had a randomized, double-blinded 2 £ 2
factorial design. Sixty-six healthy men aged 18–40 years
were randomized to FO or OO (control) capsules (5 ml/d)
and to either sunflower oil and Becel 60 margarine (S/B) or
to rapeseed oil and a Danish rapeseed oil-enriched butter
spread, Kaergaarden Light (R/K). The participants were
instructed to use it for cooking, baking and on bread as substi-
tutes for the oil and spreads that they normally used. Apart
from being high and low in 18: 2n-6, respectively, the two
fat combinations were also chosen because of their relatively
high (.10:1) and low (approximately 2:1) ratio between n-6
and n-3 PUFA (Table 1). The oils were a kind gift from
Aarhus United Denmark A/S (Aarhus, Denmark) and packed
in identical, neutral 500 ml bottles. The spreads were
kindly provided by Unilever Danmark A/S Foods (Brøndby,
Denmark) and Arla Foods amba (Viby, Denmark) and
packed in identical, white 250 g containers. The capsules
were a kind gift from Pharma Nord ApS (Vejle, Denmark)
and provided as 660 £ 0·5 ml soft gelatine capsules with
either FO (Bio-Marine, NEFA) or OO (TAG). Randomization
was done separately for the fat and the capsule intervention by
drawing notes from two envelopes. The capsule containers
were numbered continuously to ensure that neither subjects
nor investigators knew who were in the same capsule group.
For logistic reasons, this could not be done with the fat inter-
vention, so the fat groups were coded A and B. All allocations
were blinded to the participants and investigators until the end
of data analysis. However, when asking the participants after
the intervention, 80 % correctly guessed which type of
capsules they had received, due to the fishy taste of the FO.
Less than 10 % correctly guessed what type of cooking oil
they had been using, whereas about 45 % guessed that they
had been using a butter spread or a margarine. Prior to the
intervention period, the participants were provided with OO
Table 1. Nutritional contents of oils, fats and capsules used in the study*†
Run-in fats
(per 100 g) Intervention fats (per 100 g)
Intervention capsules‡
All groups S/B R/K (per ten capsules)
Olive oil Butter Sunflower oil Becel Margarine Rapeseed oil Kaergaarden spread FO OO
Energy (kJ) 3800 3010 3800 2250 3800 2250 220 220
Protein (g) 0 ,1 0 0 0 ,1 1·2 1·2
Carbohydrate (g) 0 ,1 0 0 0 ,1 0·6 0·6
Fat (g) 100·0 80·0 100·0 60·0 100·0 60·0 5·0 5·0
SFA (g) 13·7 48·8 10·5 11·0 8·5 23·3 0·1 0·1
MUFA (g) 74·8 24·9 28·1 17·0 57·9 26·4 0·7 4·4
PUFA (g) 6·5 2·3 56·4 29·1 28·7 7·3 4·0 0·3
18: 2n-6 (g) 5·8 1·6 56·1 24·5 20·4 4·9 0·0 0·3
18: 3n-3 (g) 0·7 0·5 0·3 4·5 8·3 2·3 0·0 0·0
20: 5n-3 (g) 0·0 0·1 0·0 0·0 0·0 0·0 2·0 0·0
22: 5n-3 (g) 0·0 0·0 0·0 0·0 0·0 0·0 0·3 0·0
22: 6n-3 (g) 0·1 0·0 0·0 0·0 0·0 0·0 1·2 0·0
n-6: n-3 PUFA 8·1 2·9 221·1 5·4 2·5 2·2 0·1 6·8
S/B, sunflower oil/Becel margarine; R/K, rapeseed oil/Kaergaarden spread.
* For details of subjects and procedures, see Methods.
† Based on the National Danish Food Composition Tables20, information from the manufacturers and our own laboratory analyses.
‡ The fish oil (FO) was provided as NEFA and the olive oil (OO) as TAG. Ten capsules contained 5 ml oil. The fish oil capsules also contained 0·67 g/l a-tocopherol.
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and butter for 2 weeks (run-in) to standardize their fat con-
sumption and PBMC fatty acid composition. During the run-
in and intervention period the participants were not allowed
to eat fish except for five lean fish types (canned tuna in
water, cod, coalfish, plaice, shrimps and shellfish), which
were allowed once per week. There were no dietary restric-
tions during the wash-out period. Apart from these changes,
the participants were told to maintain their dietary and life-
style habits throughout the study.
Participants were recruited by notes at universities through-
out Copenhagen. Written information was sent out by email
and the inclusion criteria were checked by telephone screening.
Eligible subjects were invited to an information meeting
where verbal information on the study was given. The study
protocol was approved by the Scientific Ethical Committee
of Frederiksberg and Copenhagen (J.no. KF 01267804) and
registered in the US National Institutes of Health clinical trial
database (ClinicalTrials.gov, no. NCT00266292). Informed
written consent was obtained from all participants.
Eligible persons were apparently healthy 18–40 year old
males with no chronic diseases, no regular medication and
no strong allergies, who were smoking less than five ciga-
rettes/week, exercising ,7 h/week, eating home-made meals
$5 d/week and who had a daily consumption of butter,
margarine and/or oil. Blood donation or dietary supplements
such as vitamins were not allowed 2 months before or
during the study. Most of the participants were students.
Two participants abandoned the study during the intervention
period, one due to personal problems and one because of
trouble swallowing the capsules. Accordingly, sixty-four
participants completed the intervention period, after which
one person in the OO þ R/K group withdrew without
explanation.
Visits and measurements
The present study included four examination visits to the
Department of Human Nutrition: 1) before the start of
the 2-week run-in-period; 2) at baseline before the start of
the intervention; 3) after 8 weeks of intervention; 4) after
8 weeks of wash-out. Dietary intake was recorded three
times by 4-d weighed dietary records on three workdays and
a Saturday, just before the start of the run-in period and
before visits 3 and 4. Nutritional calculations were done
with Dankost 3000w software (Dansk Catering Center,
Herlev, Denmark) based on the National Danish Food Compo-
sition Tables20 but with the specific fatty acid composition
of the intervention spreads and oils entered into the database.
At every visit the participants filled out questionnaires on
illnesses, use of medication, dietary habits and use of fats
and oils. The median length of the intervention and wash-
out periods were 8 (range 7–9) weeks and 8 (range 7–8)
weeks, respectively, and did not differ between the groups
(P.0·17, Kruskall-Wallis test).
At the first visit, height and weight were measured by stan-
dard procedures. Instructions on food recording were given
and diet registration forms and a kitchen scale were provided.
The participants were asked to hand in the completed dietary
records and the scale to a dietitian a couple of weeks later and
to pick up new forms and a scale before the second and third
food recording. Finally, 500 ml bottles of OO (Oleificio R. M.
s.p.a., Lucca, Italy) and 500 g packs of butter (a kind gift from
Arla Foods amba) were provided to the participants. They
were instructed to use it after finishing the first dietary recording
and to discard all other types of oil, butter and margarine in
the household. On the second visit, participants received
their allocated capsules and fats. As in the run-in period,
they were told to use the fats instead of their usual butter, mar-
garine and oils and to pick up more if they ran out. Since no
fixed amounts were set, they were allowed to share it with
other members of their household. They were also told to con-
sume the capsules in combination with a meal, to return the
remaining capsules at the end of the intervention period and
to bring back remaining oils and spreads to ensure their use
only during the intervention. No fats or oils were provided
in the wash-out period, where the participants were asked to
eat their habitual diet. Counting of the returned capsules
showed that the median FO and OO consumption during the
intervention was 4·4 (range 2·0–5·6) ml/d in both groups.
Based on the dietary records, the median consumption of the
provided intervention fats was 3·4 g/d spread (0·0–32·5 g/d)
and 10·3 g/d oil (0·0–52·5 g/d) with no significant differences
between the groups (P.0·78, Kruskal–Wallis test). There
were 12 % and 31 % of the participants in the OO and FO
groups, respectively, who had episodes of nausea, slight
headache or felt bloated during the supplementation period,
likely due to the gelatine in the capsules or the fishy taste of
the FO capsules.
At the second, third, and fourth visit a number of cardiovas-
cular measurements were performed and blood was sampled.
Participants were instructed to be 12 h fasted (except for 0·5
litres water), not take any medication or drink alcohol 24 h
prior to the blood sample and to avoid exercise the last 36 h.
They were also told not to smoke the last week, to have the
same meal every night before the blood sample and to
reschedule their visit if they were ill. These criteria were
checked at every visit. Finally, the participants received a
breakfast meal, kindly sponsored by Arla Foods amba and
Lantma¨nnen Schulstad A/S (Hvidovre, Denmark).
Laboratory analyses
For isolation of PBMC, blood was sampled with Na-heparin
and diluted 1:1 in sterile RPMI-1640 culture medium
(# BE12-167F; Lonza, Basel, Switzerland) with 1 % antibiotics
(10 000 units penicillin/10 000 mg streptomycin, # P4333;
Sigma-Aldrich, Mannheim, Germany) within 30 min, layered
on Ficoll-Paque Plus (# 17144003; Amersham Biosciences,
Piscataway, NJ, USA) and centrifuged for 30 min at 950 g,
208C. PBMC were isolated from the interface and washed
twice in ice-cold RRMI medium by centrifugation at 700 g,
208C, 10 min. PBMC from 20 ml blood (about 2–4 £ 107
cells) were resuspended in 1·5 ml methanol with 0·01 % buty-
lated hydroxytoluene, sealed with N2 and frozen at 2808C
within 6 h after sampling. Lipids were extracted by the
Folch procedure21 and transmethylated with boron trifluoride
in methanolic NaOH. The resulting fatty acid methyl esters
were separated by GLC on a HP-6890 Series II chromatograph
(Hewlett-Packard Inc., Waldbronn, Germany) with an injec-
tion volume of 5ml, split-ratio 10:1 and injector and detector
temperatures of 2508C and 3008C, as described elsewhere22.
About 98 % of the fatty acids in the chromatograms were
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identified, corresponding to a mean of 222 (range 93–408) mg
fatty acids in PBMC in one sample. The intra- and inter-assay
variations were quantified by analysis of a reference sample. If
the reference sample in a given assay deviated more than 3 SD
from its usual value, the whole assay was re-analysed. Intra-
and inter-assay CV were 1·1 and 2·4 % for SFA, 0·8 and
1·8 % for MUFA, 1·8 and 2·3 % for n-6 PUFA and 4·8 and
6·1 % for n-3 PUFA, respectively. The relative content of
specific fatty acids is expressed as an area percentage relative
to all fatty acids in a chromatogram, comparable to g/100 g.
The fatty acid composition of the spreads, oils and oil capsules
were also analysed by the afore-mentioned procedures.
Statistical analyses
Data were checked for normal distribution with the Shapiro-
Wilk normality test and visual inspection of histograms.
Dietary 18: 3n-3 and n-6: n-3 PUFA and 20: 5n-3 in PBMC
were logarithmically transformed before analysis. Compari-
sons between the four intervention groups at baseline were
done in one-way ANOVA with Tukey’s post hoc test. Com-
parisons after the intervention and after the wash-out period
were done in analysis of covariance with fat type and capsule
type as fixed factors and baseline values as covariate, after
checking for interaction. To further check for changes
during each period in each group, paired t tests were used.
Bivariate correlations were done with Pearson’s correlation
analysis. All data were analysed with the Statistical Package
for the Social Sciences software (version 14·0; SPSS Inc.,
Chicago, IL, USA) and statistical significance was established
at P,0·05.
Results
There were no significant differences in age, anthropometry or
self-reported fish consumption between the four groups at
baseline (Table 2). Although 30 % of the participants reported
occasional (less than weekly) intake of oily fish during the
intervention, the restriction on oily fish was generally
undertaken. Data from the weighed dietary records (Table 3)
showed that the participants’ energy and macronutrient
intake was close to the Nordic recommendations23 and, apart
from a slightly lower fat intake, corresponded well to that of
the general Danish male population24. The dietary composition
is shown without contributions from alcohol. Based on the
dietary records, the median alcohol consumption during the
intervention was 3, 1, 10 and 24 g/d in the four groups
shown in Table 3, but based on the questionnaire it was 10,
0, 0 and 9 g/d. The reported energy intake remained constant
throughout the study in all four groups, whereas the relative
contribution of energy from fat tended to increase in the inter-
vention period, where the participants received oil capsule
supplements (Table 3).
The fat intervention mainly changed the composition of
dietary fat in the S/B groups, resulting in higher 18: 2n-6
and total PUFA intake and lower intake of MUFA relative
to the R/K groups (Table 3). 18: 2n-6 constituted 7 (SD 2)
E% and 4 (SD 1) E% in the S/B groups and R/K groups,
respectively, in the last week of the intervention period. The
consumption of 18: 3n-3 tended to increase slightly in all
groups, but did not differ between the S/B groups and the
R/K groups (Table 3). The FO groups had significantly
higher n-3 PUFA intake than the OO groups. Accordingly,
the dietary n-6:n-3 PUFA ratio was affected by both
interventions. No differences were seen in the intake of
oleic acid (18: 1n-9) (Table 3).
No significant interactions were seen between the fat and
capsule intervention on n-3 LCPUFA incorporated in
PBMC. This indicates that the effect of the FO capsules did
not depend on the type of provided dietary fats. As expected,
the FO capsules resulted in markedly lower PBMC 20: 4n-6
and higher n-3 LCPUFA than the OO capsules (Table 4).
PBMC 22: 5n-3 was slightly higher and 20: 5n-3 tended to
be slightly higher (P¼0·06) in the R/K groups, but no
differences were seen for 22: 6n-3. The fat intervention gave
lower PBMC MUFA in the S/B groups compared with the R/
K groups and tended to increase PBMC n-6 PUFA (P¼0·06).
In within-group comparisons, 18: 2n-6 was found to
increase with S/B, but only when FO capsules were given
(Table 4), possibly due to negative feedback inhibition of
the D6-desaturase by the FO25. Overall, incorporated n-3
PUFA increased and n-6 PUFA decreased when moving
Table 2. Baseline characteristics of the study participants in the four intervention groups*†
(Mean values and standard deviations)
Olive oil capsules Fish oil capsules
S/B (n 16) R/K (n 17) S/B (n 17) R/K (n 14)
Mean SD Mean SD Mean SD Mean SD
Age (years) 24·9 3·9 25·5 4·4 26·3 4·8 24·9 4·9
Height (m) 1·79 0·05 1·84 0·06 1·83 0·07 1·85 0·07
Weight (kg) 74·3 7·4 79·3 9·3 73·8 7·9 78·2 10·2
BMI (kg/m2) 23·1 1·9 23·3 1·9 21·9 1·6 22·9 1·9
Fish consumption $ weekly
n 4 1 2 5
% 25 6 12 36
S/B, sunflower oil/Becel margarine; R/K, rapeseed oil/Kaergaarden spread.
* For details of subjects and procedures, see Methods.
† The intervention groups were compared in one-way ANOVA except for fish consumption, which is shown as number of persons who consumed fish at least weekly and was
tested with two-sided x2 test. No significant differences were seen for any of the variables.
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Table 3. Intake of macronutrients in the intervention groups at baseline, after the intervention and after the wash-out period (n 63-64)†‡
(Values are means and standard deviations except for 18: 3n-3 and the PUFA ratio, which are given as medians (25th, 75th percentiles))
Olive oil capsules Fish oil capsules
S/B R/K S/B R/K P values
Mean SD Mean SD Mean SD Mean SD Capsule Fat
Energy (kJ/d) Baseline 11 539 2768 12 266 2714 12 216 2151 11 558 1942 0·73
Intervention 11 107 2210 11 389 2640 12 104 2933 11 417 2834 0·38 0·72
Wash-out 10 635 2130 11 916 3031 11 578 3276 10 779 2421 0·98 0·80
Protein (E%) Baseline 15 2 16 2 14 2 15 2 0·26
Intervention 14 2 15 3 16 2 14 2 0·29 0·11
Wash-out 15 2 16 3 15 2 14 2 0·05 0·85
Carbohydrate (E%) Baseline 52 6 50 6 53 5 50 7 0·40
Intervention 51 5 48 5 51 7 48 6 0·66 0·23
Wash-out 54 4 51 5 52 7 50 6 0·14 0·48
Fat (E%) Baseline 33 6 35 6 33 5 35 6 0·65
Intervention 35 5 36 4 35 7 37 7 0·41 0·54
Wash-out 31* 5 32* 4 34 6 36 6 0·02 0·48
SFA (g/d) Baseline 39 13 42 16 39 11 40 11 0·96
Intervention 31* 8 37 11 35 13 40 15 0·20 0·10
Wash-out 32 10 37 14 37 11 36 11 0·42 0·74
MUFA (g/d) Baseline 33 10 38 13 36 9 36 9 0·49
Intervention 34 6 40 12 35 12 43 14 0·64 0·02
Wash-out 30 9 36 12 34 12 33 13 0·71 0·60
18: 1n-9 Baseline 26·0 8·8 32·2 12·2 29·4 8·2 28·5 7·9 0·31
Intervention 28·1 5·7 31·0 9·6 29·9 9·4 32·2 12·2 0·52 0·36
Wash-out 24·5 8·4 28·1 8·9 29·1 11·5 27·1 11·7 0·43 0·93
PUFA (g/d) Baseline 14 6 17 5 17 4 18 8 0·25
Intervention 22** 8 15 5 27*** 7 21 6 ,0·01 ,0·001
Wash-out 13*** 4 17 6 15*** 5 16* 5 0·74 0·17
n-6 PUFA (g/d) Baseline 12 5 13 4 13 4 14 5 0·53
Intervention 19*** 7 12 4 21*** 6 13 4 0·43 ,0·001
Wash-out 10*** 4 13 4 12*** 5 12 5 0·50 0·40
18: 2n-6 Baseline 11·4 5·3 13·2 4·1 12·8 3·5 13·8 5·3 0·54
Intervention 19·3*** 7·0 12·3 4·3 20·7*** 6·0 13·1 3·9 0·52 ,0·001
Wash-out 10·3*** 3·7 12·6 4·4 12·2*** 4·5 12·3 4·6 0·49 0·40
n-3 PUFA (g/d) Baseline 2 1 3 1 2 1 3 3 0·15
Intervention 3* 2 3 1 6*** 1 7*** 3 ,0·001 0·70
Wash-out 2 1 3 1 2*** 2 3*** 1 0·46 0·21
18: 3n-3 Baseline 1·6 0·9; 2·3 2·3 1·6; 2·9 1·7 1·4; 2·2 1·8 1·6; 2·7 0·27
Intervention 2·5** 1·8; 3·4 2·6 2·1; 3·4 2·7** 2·2; 3·4 2·7* 2·2; 3·4 0·48 0·77
Wash-out 1·6** 1·2; 2·0 2·1* 1·5; 2·8 1·5** 1·3; 2·4 1·7* 1·4; 2·4 0·99 0·12
n-6: n-3 PUFA Baseline 6·6 4·9, 8·4 5·3 3·7, 7·2 6·2 4·7, 7·6 5·2 3·7, 7·7 0·22
Intervention 7·1 5·7, 8·8 4·0 3·7, 4·6 3·5*** 2·9, 3·7 2·0*** 1·6, 2·3 ,0·001 ,0·001
Wash-out 5·5* 4·3, 6·7 5·2 3·4, 6·5 5·4*** 4·1, 8·6 4·5*** 3·3, 7·0 0·98 0·63
S/B, sunflower oil/Becel margarine; R/K, rapeseed oil/Kaergaarden spread; E%, percentage of total energy intake.
Changes during each period within each group were tested with paired t test. Mean value was significantly different from that of the preceding visit: *P,0·05; **P,0·01; ***P,0·001.
Baseline values were tested in one-way ANOVA comparing the four groups. After the intervention and wash-out period the groups were compared in analysis of covariance, adjusting for the two interventions and baseline values.
P values are shown for the two interventions (capsule and fat).
† Contributions from the oil capsules are included in the numbers; reported alcohol consumption is not included.
‡ For details of subjects and procedures, see Methods.
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from left to right in Table 4, but the effect of the FO sup-
plement was much stronger than that of changing the 18:
2n-6 intake.
After the wash-out period the dietary data showed that the
participants had actually returned to their habitual diet
(Table 3). PBMC 20: 5n-3, 22: 5n-3 and in particular 22:
6n-3 were still increased in the FO groups, compared with
values at baseline (Table 4). Slight effects of the fat interven-
tion were also seen on PBMC 20: 4n-6, 20: 5n-3, 22: 5n-3 and
the n-6:n-3 PUFA ratio after 8 weeks of wash-out.
The proportion of n-3 LCPUFA in PBMC at the end of the
intervention was strongly correlated with the reported intake
of n-3 PUFA (r 0·70, P,0·001, n 64) and also when the
numbers were evaluated as changes during the intervention
(r 0·69, P,0·001, n 64). The overall pattern in PBMC
n-6:n-3 PUFA (Table 4) corresponded well to the reported
ratios in the diet (Table 3).
Discussion
In the present study, we found clear effects of FO on PBMC
n-3 LCPUFA, but no profound differences in 22: 6n-3 or
other n-3 LCPUFA as a result of the fat intervention. This
is in accordance with a recent tracer study by Goyens
et al.17, who investigated the effect of dietary 18: 2n-6:18:
3n-3 ratios between 19:1 and 7:1 at 18: 2n-6 intakes of 3–
7 E % in elderly subjects. In their study, 20: 5n-3 in plasma
phospholipids increased at both low 18: 2n-6 and high 18:
3n-3 intake, but 22: 6n-3 was only slightly increased and
only in the group with high 18: 3n-3, indicating no change
in the rate of conversion of 20: 5n-3 to 22: 6n-3. A number
of studies13 – 16 have sought to increase the endogenous
synthesis of 22: 6n-3 by increasing the consumption of 18:
3n-3, whereas we aimed at a similar intake of 18: 3n-3
in all groups, since a high consumption of 18: 3n-3 may
Table 4. Peripheral blood mononuclear cell fatty acid composition (FA%) in the intervention groups at baseline, after the intervention and after the
wash-out period (n 63–64)†‡
(Values are means and standard deviations except for 20: 5n-3, which is shown as median (25th, 75th percentile))
Olive oil capsules Fish oil capsules
S/B R/K S/B R/K P values
Mean SE Mean SE Mean SE Mean SE Capsule Fat
SFA Baseline 36·8a,b 0·8 37·8b 0·5 34·9a 1·1 37·9b 0·5 0·03
Intervention 37·5 0·2 37·4 0·2 38·0* 0·3 37·3 0·6 0·54 0·26
Wash-out 38·2 0·4 38·2** 0·3 37·8 0·2 38·7 0·4 0·97 0·16
MUFA Baseline 18·6 0·4 18·2 0·2 18·9 0·4 18·0 0·2 0·21
Intervention 17·4* 0·3 18·6* 0·2 17·6** 0·2 18·3 0·3 0·86 ,0·001
Wash-out 17·4 0·2 18·0* 0·3 17·7 0·2 17·9 0·4 0·61 0·07
PUFA Baseline 41·4 0·4 41·2 0·3 41·9 0·7 41·0 0·4 0·55
Intervention 41·4 0·3 40·9 0·2 41·0 0·2 40·6 0·5 0·22 0·26
Wash-out 41·2 0·3 41·2 0·3 41·2 0·4 40·7 0·4 0·50 0·69
n-6 PUFA Baseline 35·0 0·3 35·2 0·3 35·8 0·7 34·8 0·4 0·44
Intervention 35·3 0·3 34·7 0·2 30·6*** 0·3 29·9*** 0·5 ,0·001 0·06
Wash-out 34·8 0·3 34·6 0·3 34·5*** 0·4 33·3*** 0·4 0·02 0·08
18: 2n-6 Baseline 7·3 0·2 7·2 0·2 7·4 0·2 7·3 0·2 0·81
Intervention 7·3 0·2 6·9* 0·2 8·1** 0·2 7·1 0·3 Interaction P¼0·05
Wash-out 7·0 0·2 7·2 0·2 7·5** 0·2 7·6* 0·3 0·04 0·12
20: 4n-6 Baseline 22·6 0·26 23·1 0·2 23·5 0·6 22·7 0·3 0·30
Intervention 23·0 0·26 22·9 0·2 19·1*** 0·3 19·6*** 0·4 ,0·001 0·35
Wash-out 22·9 0·26 22·6 0·3 22·4*** 0·3 21·4*** 0·3 ,0·001 0·02
n-3 PUFA Baseline 6·3 0·2 6·0 0·2 6·1 0·1 6·2 0·1 0·55
Intervention 6·1 0·2 6·2 0·2 10·4*** 0·3 10·7*** 0·2 ,0·001 0·10
Wash-out 6·4 0·2 6·6 0·3 6·7*** 0·2 7·4*** 0·3 0·009 0·07
20: 5n-3 Baseline 0·4 0·4-0·5 0·5 0·4-0·6 0·5 0·4-0·6 0·5 0·4-0·6 0·36
Intervention 0·3* 0·3-0·5 0·4 0·4-0·5 2·6*** 2·1-3·2 2·7*** 2·5-3·1 ,0·001 0·06
Wash-out 0·4* 0·3-0·6 0·6* 0·4-0·7 0·6*** 0·5-0·8 0·6*** 0·5-1·3 0·001 0·05
22: 5n-3 Baseline 2·6 0·1 2·6 0·1 2·6 0·1 2·5 0·1 0·83
Intervention 2·6 0·1 2·8** 0·1 4·0*** 0·1 4·2*** 0·1 ,0·001 0·02
Wash-out 2·7 0·1 2·8 0·1 2·7*** 0·1 2·9*** 0·1 0·55 0·04
22: 6n-3 Baseline 2·9 0·2 2·7 0·1 2·7 0·1 2·8 0·1 0·54
Intervention 2·7 0·1 2·6 0·1 3·4*** 0·1 3·5*** 0·1 ,0·001 0·83
Wash-out 2·8 0·1 2·9 0·2 3·0** 0·1 3·3 0·1 0·002 0·08
n-6: n-3 PUFA Baseline 5·6 0·2 5·9 0·2 5·9 0·2 5·6 0·2 0·39
Intervention 5·9 0·2 5·7 0·2 3·0*** 0·1 2·8*** 0·1 ,0·001 0·08
Wash-out 5·5* 0·2 5·4 0·2 5·2*** 0·1 4·6*** 0·2 ,0·001 0·02
FA%, area percentage of a given fatty acid relative to all fatty acids in a chromatogram; S/B, sunflower oil/Becel margarine; R/K, rapeseed oil/Kaergaarden spread.
Mean values within a row with unlike superscript letters were significantly different (P,0·05) (Tukey’s post hoc test). After the intervention and wash-out period the groups
were compared in analysis of covariance, adjusting for the two interventions and baseline values. P values are shown for effect of the two interventions (capsule and fat).
Baseline values were tested in one-way ANOVA comparing the four groups. Changes during each period within each group were tested with paired t test.
Mean value was significantly different from that of the preceding visit: *P,0·05; **P,0·01; ***P,0·001.
† No 20: 3n-9 was detected in any of the samples.
‡ For details of subjects and procedures, see Methods.
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theoretically inhibit the D6-desaturase12. As reviewed by
Burdge and Calder11, most studies have failed to show
increases in synthesis and incorporation of 22: 6n-3 by
increasing the 18: 3n-3 intake and/or decreasing dietary 18:
2n-6. However, it could be speculated that 22: 6n-3 synthesis
would be increased if the 18: 2n-6:18: 3n-3 ratio and the 18:
2n-6 intake were even lower than in the study by Goyens
et al.17. In a study in piglets where the intake of 18: 2n-6
was kept constant, Blank et al.12 showed maximal incorpor-
ation of 22: 6n-3 when the 18: 2n-6:18: 3n-3 ratio was 2:1
to 4:1, indicating that a high consumption of both 18: 2n-6
and 18: 3n-3 limited the production and/or incorporation of
22: 6n-3. However, in line with the existing evidence we
saw no effect on PBMC 22: 6n-3 despite the low 18: 2n-
6:18: 3n-3 ratio (4:1) combined with a low 18: 2n-6 intake
(4 E%) in the OO þ R/K group. Comparable intakes of 18:
2n-6 and 18: 3n-3 were tested in a recent Canadian cross-
over study19 in healthy men, where the dietary 18: 2n-6:18:
3n-3 ratios were manipulated from 4:1 to 10:1 at 18: 2n-6
intakes of 3·8–10·5 E% by providing specially produced
foodstuffs to the participants. Again, no effect was seen on
22: 6n-3 in plasma phospholipids. We cannot exclude the
possibility that 22: 6n-3 incorporation may be increased at a
18: 2n-6 intake ,4 E%, but this would probably require diet-
ary manipulations that are difficult to achieve with a normal
diet and therefore of questionable relevance for recommen-
dations to healthy individuals.
Our second aim was to test the widespread view held by
Hibbeln and others2 that a high 18: 2n-6 intake in the diet
affects the incorporation of preformed dietary n-3 LCPUFA,
in this case from FO. We did not find support for this hypoth-
esis, as no interaction between the interventions were observed
and only minor differences in PBMC n-3 LCPUFA content
were seen between the two FO-supplemented groups. To our
knowledge, the combination of FO supplementation and a
high 18: 2n-6 diet has not been investigated in other
randomized human trials. One study in rats fed either purified
20: 5n-3 or 22: 6n-3 showed a decrease in tissue phospholipid
20: 5n-3, but virtually no change in 22: 6n-6 when increasing
amounts of 18: 2n-6 rich maize oil were included in the
background diet26.
The slight increase in PBMC 22: 5n-3 in the R/K groups is
in line with the findings of human trials investigating the
effects of increasing the 18: 3n-3 intake (see ref. 11) or low-
ering the 18: 2n-6 intake14,17. In contrast to a study by Chan
et al.14, we did not see any marked differences between the
fat groups in tissue 20: 5n-3, possibly because a larger differ-
ence between the groups were provoked in their study, or
because 20: 5n-3 was further converted to 22: 5n-3 in the cur-
rent study. According to the present data, the most efficient
way of achieving a higher proportion of 22: 6n-3 and other
n-3 LCPUFA in tissues is by increasing the intake of pre-
formed 20: 5n-3 and 22: 6n-3 from oily fish or FO. It
should be noted, however, that some effects of our fat inter-
vention were seen 8 weeks after the participants had returned
to their normal diet. This may be important for n-3 PUFA
status over time.
For logistic reasons, the encapsulated FO was provided as
NEFA, whereas the placebo capsules contained OO in the
form of TAG. This is a limitation in the present study but
we believe that it did not have any considerable effect on
our results since the absorption and incorporation of these
two forms of PUFA have been shown to be very similar27 – 29.
The strength of the present study is that it was conducted in a
real-life-setting, which manipulated only the intake of com-
mercially available fats and oils. On the other hand, this
gives rise to limitations with regard to determination of the
intake of specific fatty acids. The data from the 4-d weighed
dietary records are accurate with regard to macronutrient
intake but although we added the fatty acid composition of
the provided fats and oils to the database, the National
Danish Food Composition Tables do not provide information
on fatty acid composition of all foodstuffs that were eaten.
After subtracting 5 % assumed to be glycerol backbones,
about 10 % of the total fat intake was still unexplained in
terms of fatty acids. Therefore, the intake numbers on indi-
vidual fatty acids should be interpreted with caution. The
effects on tissue incorporation were determined in PBMC,
since another purpose of the study was to explore inflamma-
tory aspects of the interventions. Due to the short leukocyte
lifetime, the PBMC fatty acid composition is believed to
reflect tissue changes in the relevant period, with maximal
incorporation after about 2 weeks30. Since consumption of
FO affects the proportion of 22: 6n-3 and in particular 20:
5n-3 in a dose–responsive manner, PBMC was also a
highly relevant marker of compliance with the FO capsules.
In conclusion, increasing the dietary 18: 2n-6 intake by
providing different commercially available fats and oils to
healthy men did not affect either the 22: 6n-3 content in
PBMC nor the incorporation of n-3 LCPUFA from FO
supplements in these cells.
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